A detailed history of Price T Rowe Associates Inc transactions in Hille Vax, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,063 shares of HLVX stock, worth $19,522. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,063
Holding current value
$19,522
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.86 - $15.93 $119,347 - $160,303
10,063 New
10,063 $146,000
Q2 2022

Aug 15, 2022

BUY
$8.7 - $20.18 $9.58 Million - $22.2 Million
1,101,237 New
1,101,237 $12 Million

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $64.8M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.